Categories
Report

SER

***Sponsored by LFG Equities Corp

Serina Therapeutics, Inc.’s cover photo

‍

SER founders developed the first-generation of “PEGylated” drugs, which became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales

Their lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025

SER has a Float of Roughly 3.3 Million According to the Leading Charting Site Finviz

Check Out the Investor Presentation Here

‍_________________________

Hello Everyone,

We are in the midst of an incredible market. I was just looking at all of our profiles from September and we have shucked out some significant movers in the past month. I am going to put an update together this week but I encourage you to look at all of the companies that we have profiled over the past month and take a look at how they have performed.

Look at the overall picture and you will see a testament to the strength of the market and not just one particular sector.

For tomorrow we have something that is virtually undiscovered, which is a GREAT catalyst because of the size of the float. According to all of my research, this one has a TINY float of just about 3.3 million according to Finviz. With only 10M outstanding and 47% insider ownership, this one has an extremely favorable structure right now.

Pull up SER right away.

With a focus on next-generation molecules, their work spans diverse central nervous system disorders and beyond.

SER has ongoing collaborations with specialized partners that support the exploration of novel RNA-based medicines targeting vaccine immunology, cancer immunotherapy, and gene therapy.

This forward-thinking approach to drug discovery highlights a commitment to unlocking new possibilities in medicine, making the company well worth closer attention for those interested in emerging therapeutic frontiers.

This one has an interesting story behind it. The founders already did it once. This company was founded in 2007 and was largely funded by the founders and certain investors who followed the team to Serina after the successful exit (via acquisition by Nektar Therapeutics) of the founding team’s prior company, Shearwater Polymers.

At Shearwater, Serina co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of “PEGylated” drugs. PEG (polyethylene glycol) technology became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales. Serina was founded to engineer a next generation polymer therapeutic (our POZ PlatformTM) to address the limitations of PEG and other biocompatible polymer technologies — enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.

Serina Therapeutics’ proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline).

During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.”

This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates.As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations.

While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules.

POZ Delivers Key Advantages

POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.

Enabling Continuous Drug Delivery

Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously.

They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure.

They have to be monitored and dose adjusted with greater frequency, and on an individual basis.

These fluctuations present clinical, compliance and quality of life challenges for many patients.

Administered Subcutaneously, POZ Provides Extended Delivery

Serina is in the process of developing proprietary drugs to treat neurological diseases. Their lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025. Their current discovery and development work includes a focus on unlocking the potential of cannabinoids and other molecules across a range of CNS indications and beyond. Their POZ platform partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.

Their proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).

The technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.

About SER-252 (POZ-apomorphine)

SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.

dosed via IV, SC or IM routes to address a broad range of clinical indications.

Our proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.

POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to proteins, aptamers and other classes of molecules.

‍

Their largest shareholder, Juvenescence Ltd., just secured $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.

This significant investment and accompanying strategic alliance will accelerate Juvenescence’s mission to develop innovative therapies targeting age-related diseases and extending healthspan. As part of this partnership, Juvenescence and M42 will launch a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with cutting-edge data and clinical infrastructure to speed the development of novel therapeutics.

Juvenescence has been a critical partner to Serina, providing strategic guidance and capital that has helped them advance their POZ Platform™ into the clinic.

RECENT HIGHLIGHTS
  • Advancement of SER-270 for Tardive Dyskinesia: In July 2025, Serina announced the advancement of SER-270 (POZ-VMAT2i), a once-weekly injectable therapy for tardive dyskinesia (TD), enabled by the POZ Platform. The program aims to address unment needs in TD treatment, particularly for institutional use and adherence challenges. SER-270 may also be evaluated for Huntington’s disease chorea, a high need indication with limited long-acting injectable (LAI) options.
  • Board Appointments: In May 2025, Serina appointed Stephen (Steve) Brannan, M.D. to its Board of Directors. Mr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Dr. Brannan held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, focusing on clinical programs for depression, Alzheimer’s, schizophrenia, and epilepsy. Most recently, as Chief Medical Officer at Karuna Therapeutics, he led the clinical strategy for KarXT (xanomeline–trospium), the first new schizophrenia treatment in over 30 years, which was key in Karuna’s $14 billion acquisition by Bristol Myers Squibb in 2024. This addition strengthens Serina’s Board as the company advances its innovative therapeutic pipeline toward the clinic.
  • $5 Million in Funding: In April 2025, Serina secured $5 million from strategic shareholders to support the continued development of SER-252 (POZ-apomorphine), Serina’s lead clinical candidate for Advanced Parkinson’s disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
  • Financing via ATM: In April 2025, Serina entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC with respect to an at the market offering program under which the Company may offer and sell $13.3 million of shares of Serina common stock in “at-the-market” (ATM) offerings. As of August 8, 2025, Serina issued 199,562 shares of common stock at a gross average price of $5.95, resulting in net proceeds of $1.2 million.

NEWS‍


Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Sep 9, 2025

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

Aug 25, 2025

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 29, 2025

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 28, 2025

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025


Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “Is the Beaten Down Biotech Sector the Smartest Bet in Today’s Volatile Market?”

Jun 9, 2025

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

Apr 8, 2025

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025

MANAGEMENT

Simba-Gill

‍

Simba Gill, Ph.D.
Executive Chairman

Simba has a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key executive roles at Maxygen, Systemix, Boehringer Mannheim and Celltech over his thirty-year career.  He has served as a partner and advisor at Flagship Pioneering where he was the founding CEO of Evelo Biosciences and as a Venture Partner at TPG where he was Founder CEO of Moksh8 Pharmaceuticals. Simba is currently a board member at Foghorn Therapeutics (NASDAQ – FHTX) and Sensorium Therapeutics. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London.

‍

‍

‍

‍

‍

Steve Ledger

‍

Steve Ledger

CEO and Director

Steve has served as CEO since March 2024 and CFO from March 2022 to March 2024. He has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early-stage companies. He is a General Partner of Form & Fiction Ventures (FFV), a venture studio that launches and invests in startup and seed stage companies focused on socially responsible initiatives. He has served in investment management roles at Caldwell Sutter Capital, Tamalpais Partners, SF Sentry Securities, Kayne Anderson, and Fidelity Investments. Mr. Ledger received a B.A. in Economics from the University of Connecticut.

‍

‍

‍

‍

‍

‍

‍

‍

‍

‍
Randall
Randall Moreadith, M.D., Ph.D.
Chief Development Officer

Randall has served as Serina’s CDO since March 2024. He served as Serina’s President, CEO, and member of Serina’s board of directors from September 2010 to March 2024. Prior to Serina, Randall served in executive leadership roles including CDO at Nektar Therapeutics, CMO of Cardium Therapeutics, CMO at Renovis, and President / co-Founder of ThromboGenics (now Oxurion). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith received his Ph.D. from Johns Hopkins University.

‍

‍

‍

‍

‍

‍

‍

Greg Curban
‍
Greg Curhan
CFO

Greg joined Serina as CFO in August 2024. He has over 35 years of operational, financial, capital markets and strategic advisory experience in various sectors including Investment Banking and Medical Device/Life Sciences. Greg has been a Partner at FLG Partners since 2020. Also since 2020, Greg has served as the CFO for Curevo Vaccines, a private biotech company focused on infectious disease immunology. As CFO, Greg has managed Finance, Legal, HR, and Investor Relations functions for Public and Private companies. He has raised equity and debt capital for both private and public companies, completed numerous successful IPOs, and executed M&A transactions, both acquiring and divesting companies. He has also served in CEO, President and Board of Director capacities. Greg earned a BA degree in Economics from Dartmouth College.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY SER AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

CETX

Sponsored by Interactive Offers, LLC

Nine months ended June 30, 2025 Revenue increased 19% to $58.0 million from $48.7 million.

Cemtrex Signs Letters of Intent for Two Strategic Acquisitions in Robotics and Aerospace that will Expand Revenues to $100 Million

CHECK OUT THE INVESTOR PRESENTATION HERE

‍_________________________

Hello Everyone,

We are coming off of a profile that just ran from 4.10 to 5.69 in a few sessions. If you have been a member for a while then you already know that is not unusual for that one. There have been a lot of movers lately. The gold company that we have been covering since $6 and as recently as 3 weeks ago when it was around $14 just broke $18 on Friday with no sign of slowing down.

We have another exciting situation with a unique catalyst that could be a potential driver for this one.

Pull up CETX right now on whatever platform you use to research exciting ideas.

First and foremost, this one just implemented a 1 for 15 reverse split last week. This has the float somewhere under 400k according to most of the sources I found including yahoo.

CETX has a few irons in the fire. Right now we see industries face increasing challenges in securing critical infrastructure and maintaining operational efficiency. Traditional security systems are struggling to keep up with modern threats, while industrial sectors require advanced, cost-effective solutions to meet growing demands.

They have revenues and are closing deals:

  • $1.2M U.S. county security project
  • $1.2M U.S. border security contract
  • $1M international deployment in Saudi Arabia
  • $800K system for a UK prison facility
  • $10.4M contract in December 2024—the largest in their history

This is just this year.

What the market lacks is a comprehensive, scalable security system that integrate AI-driven analytics and seamless cloud-based platforms. Simultaneously, industrial services providers need robust, reliable solutions for complex infrastructure projects that can be delivered with speed and precision.

CETX recognizes these gaps, offering cutting-edge, customizable security solutions and industrial services designed to enhance safety, operational effectiveness, and scalability across diverse sectors, providing much-needed innovation in critical markets.

CETX is a diversified technology company operating in the Security and Industrial sectors. Its Security segment, led by Vicon Industries, provides advanced video management software, high-performance security cameras, and integrated surveillance solutions for enterprise, government, and critical infrastructure. The Industrial segment, through Advanced Industrial Services (AIS), delivers expert rigging, mill-wrighting, process piping, and equipment installation services to manufacturers nationwide. With a focus on innovation, execution, and strategic growth, Cemtrex is committed to enhancing safety, efficiency, and value for its customers and shareholders.

Cemtrex Signs Letters of Intent for Two Strategic Acquisitions in Robotics and Aerospace

New Acquisitions Expected to Drive Total Annual Revenues to $100M and Expand Operating Profit

Hauppauge, NY, Aug. 25, 2025 (GLOBE NEWSWIRE) — Cemtrex Inc. (Nasdaq: CETX), a diversified industrial and technology company, today announced it has signed non-binding letters of intent to acquire two profitable U.S.-based businesses — one in industrial robotics integration and the other in aerospace and defense systems engineering. Combined, the two companies are expected to contribute $15–18 million in annual revenue and $2.5–3 million in operating income on a go forward basis, once closed and integrated.

“These potential acquisitions directly align with our long-term strategy to expand into high-value markets with strong macro tailwinds,” said Saagar Govil, Chairman and CEO. “We believe both businesses bring meaningful scale, margin, and strategic capabilities to the Cemtrex platform.”

The robotics integrator specializes in automation systems for agriculture and construction, expanding Cemtrex’s footprint in industrial automation and complementing its AIS division. The aerospace and defense firm delivers high-reliability communications and electronics systems for government and commercial customers, adding a new strategic vertical with long-term relevance in national security and space infrastructure.

Combined with Cemtrex’s organic growth initiatives, these acquisitions are expected to position the Company to reach $100 million in total revenue and significantly expand the Company’s operating profit. Coming off its strongest operating performance in years, Cemtrex believes these additions, if closed, will further advance its evolution into a focused, cash-generating platform spanning security technology, industrial services & automation, and next generation defense and space systems.

“This marks a meaningful step toward our goal of building a $150 million+ platform with durable earnings power and attractive operating margins,” Govil added. “Not only do these businesses add revenue and income, they bring long-term capabilities in sectors where the next decade of growth will happen.”

Both transactions are in the diligence phase and are subject to definitive agreements and customary closing conditions. Closings are expected to occur in the fourth calendar quarter of 2025. Cemtrex will provide additional updates as material developments occur.

Empowering Growth Through Two Dynamic Subsidiaries: Vicon Industries and Advanced Industrial Services (AIS)

Cemtrex Inc. (NASDAQ: CETX) is at the forefront of redefining the future of security and industrial services. Through its two key subsidiaries— Vicon Industries and Advanced Industrial Services (AIS) — Cemtrex is driving growth and innovation in rapidly expanding markets.

With the increasing global demand for smart security solutions and industrial services, Cemtrex is positioned to capture significant market share. The company’s strategic investments in AI-driven security systems and advanced industrial services are setting the stage for long-term success.

Cemtrex is committed to delivering value to its shareholders by capitalizing on market demand, executing strategic initiatives, and scaling its operations effectively. The company’s innovative products and services are key to unlocking new opportunities and sustaining growth.

As the market continues to evolve, Cemtrex is well-placed to lead with its cutting-edge solutions, unlocking substantial growth potential in the years ahead.

Their technology is impressive.

Check out this video:

CETX just released a shareholder update a few months ago. Here are some of the key points:

Vicon: Momentum, Execution, and the Launch of NEXT

Vicon, our intelligent security division, is performing. Since 2021, we’ve grown revenue from $21 million to a projected $36 million-plus for fiscal year 2025. Gross margins have improved, and our go-to-market engine is accelerating, fueled by the addition of over 60 new resellers this year alone.

Our new modular camera platform, NEXT, began shipping this quarter. It’s our most advanced product line to date—fast to install, AI-powered, visually modern, and designed to meet the complex needs of today’s enterprise and public infrastructure buyers. Early wins, including a $500K school district deployment, are encouraging. We believe this platform has the potential to become the core of Vicon’s next growth phase.

This year, Vicon has delivered:

  • $1.2M U.S. county security project
  • $1.2M U.S. border security contract
  • $1M international deployment in Saudi Arabia
  • $800K system for a UK prison facility
  • $10.4M contract in December 2024—the largest in our history

These are not pipeline projections—they’re closed deals. Vicon is performing in the market, and we are scaling it with intention.

AIS: Durable Growth with Strategic Ambition

AIS has quietly doubled in size since 2021, with revenue on track to exceed $36 million this year. Demand from food and beverage, packaging, and machinery sectors remains strong, and reshoring trends are creating more opportunity for our services.

We are no longer just a millwright and installation business. We are positioning AIS to become a full-spectrum industrial services platform, one that can handle legacy systems and lead the transition to automated, robotics-enabled manufacturing environments.

To that end, we are in advanced discussions to acquire a Midwest-based robotics integrator. This deal, if completed, would expand our capabilities into robotic workcell design, controls programming, and systems integration, allowing us to better serve manufacturers modernizing their facilities.

Our M&A playbook is disciplined. Our last acquisition was accretive, smoothly integrated, and strengthened our platform. We expect the same results as we scale.

Solana and Blockchain Infrastructure

In July, we allocated $1 million into Solana (SOL) and have since staked our holdings. We view Solana as one of the most structurally sound blockchains in production—high throughput, low latency, and deflationary mechanics hardcoded into the protocol.

This is not a hedge. It’s a strategic bet.

Blockchain infrastructure will become critical to how digital systems establish truth. Whether it’s timestamping surveillance footage, detecting tampering in AI-generated content, or anchoring public safety evidence in immutable ledgers—we believe this technology will be foundational.

Vicon has already begun R&D around blockchain-based video authentication. We intend to move quickly.

Vicon shift to AI Based Analytics solutions & Cloud based VSaaS to drive recurring revenue growth in high gross margin businesses Security segment revenues decreased 7% to $32.0M in FY’24 due to the delay of multiple projects for the segment’s products and services.

CATALYSTS:

  • AIS set to expand with strong growth in the Industrial Services market AIS segment revenues increased 39% to $34.8M in FY’24
  • Generating margin improvement through increasing prices and reducing overhead where possible Gross margin was 41% in FY’24
  • Subsequently announced a $10.4 million Valerus expansion order from a state government corrections customer and three contracts for AIS totaling $11.4 million
  • M&A strategy targeting acquisitions in high growth markets with strong ROE and attractive gross margins
  • Large, growing, addressable and mature markets in Security, Business, Manufacturing, Government & Industrial
  • Revenue for the year ended September 30, 2024, increased 13% to $66.9 million, compared to revenue in the prior year of $59.4 million.
  • Revenue for Q4’24 increased 9% to $18.1 million, compared to revenue of $16.6 million for Q4’23.
  • Vicon Innovations: Launched NEXT™ Modular Camera System, integrating groundbreaking AI analytics and Hailo-15 edge AI processing, poised to redefine the surveillance industry.

‍

Cemtrex Acquires $1 Million in Solana, Citing Structural Mispricing; Targets $10 Million Crypto Treasury Reserve

Hauppauge, NY, July 31, 2025 (GLOBE NEWSWIRE) —  Cemtrex Inc. (Nasdaq: CETX), a technology company focused on intelligent security systems and industrial services, today announced it has acquired approximately $1 million worth of Solana (SOL) as part of a new digital asset treasury strategy, with the goal of expanding its crypto reserves to $10 million over time.

“Solana is the most underappreciated layer-one blockchain in the world today,” said Saagar Govil, Chairman and CEO of Cemtrex. “It’s already processing more real-world transactions than every other blockchain combined, and it’s not even close. With a hard-coded supply curve and no reliance on fragmented scaling solutions, we believe the market has yet to appreciate what this unlocks in the next 3–5 years.”

Cemtrex purchased 5,500 SOL at an average cost of approximately $181 per token. The company intends to stake its position for on-chain yield and eventually operate its own validator node to directly participate in network security and infrastructure. Cemtrex’s longer term goal is to build a $10 million reserve position across strategic crypto networks, with Solana as the foundation.

Solana is currently processing over 1,000 transactions per second and handled more than 90 billion transactions in June 2025 alone, more than every other L1 and L2 combined. With a burn mechanism tied to usage and a hardcoded inflation schedule set to bottom out at 1.5% by 2028, we believe Solana is uniquely positioned to become a foundational layer for digital trust and settlement.

“This isn’t just a treasury hedge,” Govil added. “It’s a long-duration bet on the most capable, capital-efficient blockchain system in production and one we believe will compound its network advantage faster than the market expects. Over time, we expect Solana to outperform fiat and legacy digital assets on a structural basis.”

Cemtrex is actively exploring ways to integrate blockchain-based technologies into its product lines, including cryptographic video authentication, tamper-proof media verification, and decentralized timestamping through its subsidiary, Vicon.

“This is a long-term strategy grounded in execution. We’re putting capital and infrastructure behind it because we see where this is going,” continued Govil.

‍

Cemtrex’s Vicon Secures $1.2M Follow-On Order for County Security Infrastructure Expansion

Repeat order from major government project highlights accelerating public-sector adoption of Vicon’s video surveillance solutions

Hauppauge, NY, July 08, 2025 (GLOBE NEWSWIRE) — Vicon Industries, a subsidiary of Cemtrex Inc. (Nasdaq: CETX, CETXP) and a leading provider of advanced security and surveillance solutions, today announced that it has secured a follow-on order exceeding $1.2 million to support a major Midwestern county government security upgrade project. The order was placed through a long-standing global systems integration partner.

The scope of the project includes Vicon’s high-performance cameras, recording servers, and Valerus video management software licenses, all deployed to enhance security across multiple county facilities. This order builds on previous deployments and reflects continued customer confidence in Vicon’s reliability, scalability, and system performance. The order is expected to be fulfilled over the coming months and contribute to Vicon’s fiscal 2025 results. Consistent with the terms of the engagement, the names of the client and integration partner are not being disclosed.

“This award reflects the strength of our execution and the trust we’ve earned with key public-sector stakeholders,” said Saagar Govil, Chairman and CEO of Cemtrex. “As municipalities invest in more advanced and unified security platforms, Vicon is increasingly the partner of choice.”

This engagement marks one of Vicon’s largest public-sector wins in recent quarters and reinforces a broader pattern of repeat institutional orders, particularly in government and education verticals. While this deployment leverages Vicon’s established product lines, it comes amid growing market interest in the company’s next-generation offerings, including the award-winning NEXT Modular Sensor System, which has recently been recognized for innovation and design excellence.

“We’re seeing an encouraging pattern take hold,” Govil added. “This order is not an isolated event, it reflects growing momentum from institutional buyers who’ve deployed our systems, seen the results, and are investing further. With an expanding base of repeat government customers, visibility into our long-term growth is becoming clearer.”

Strategic Outlook

This order is further validation of Cemtrex’s ongoing strategy of transforming Vicon from a legacy camera business into a modern surveillance technology platform. The Company’s emphasis on modular design, AI-enhanced analytics, and public-sector readiness is translating into real-world traction, and into contracts with repeat customers executing multi-year infrastructure upgrades.

“We’ve spent the past several years repositioning Vicon for long-term success, and orders like this reflect that transformation taking hold,” said Govil. “We’re executing against a clear strategy, focused on delivering differentiated solutions to institutional customers, and the results are starting to materialize across our pipeline.”

Following recent industry awards, increased sales velocity, and a growing pipeline of institutional projects, Vicon is positioned to deliver meaningful year-over-year growth in fiscal 2025 and beyond.

‍

NEWS


Cemtrex Signs Letters of Intent for Two Strategic Acquisitions in Robotics and Aerospace

Aug 25, 2025

Cemtrex Reports Results for Third Quarter Fiscal 2025

Aug 14, 2025

Cemtrex Highlights $1.3 Million in Notable New Contracts in Past Week Across Security and Industrial Divisions, Reinforces FY26 Growth Outlook

Aug 13, 2025

Cemtrex Issues Shareholder Update Highlighting Growth Across Vicon and AIS Divisions, Strategic Initiatives in Blockchain and Automation

Aug 1, 2025

Cemtrex Acquires $1 Million in Solana, Citing Structural Mispricing; Targets $10 Million Crypto Treasury Reserve

Jul 31, 2025

Cemtrex’s Vicon Developing Blockchain-Based Video Integrity Layer to Combat Deepfakes and Evidence Tampering

Jul 29, 2025

Cemtrex Wins $500K+ Order for NEXT Modular Camera System From Major School District in Kentucky

Jul 10, 2025

Cemtrex’s Vicon Secures $1.2M Follow-On Order for County Security Infrastructure Expansion

Jul 8, 2025

Cemtrex’s Vicon NEXT Camera Wins Multiple Industry Awards, Signaling Commercial Momentum and Category Leadership

Jun 26, 2025

Cemtrex Accelerates Growth Strategy After Strong First Half with Targeted Acquisitions

Jun 12, 2025


Cemtrex Regains Compliance with NASDAQ Stockholders’ Equity Requirement

Jun 9, 2025

Cemtrex’s Vicon Expands Leadership in UK Prison Security Market with New Wave of System Orders

Jun 2, 2025

Cemtrex, Inc. Announces Closing of $1.25 Million Underwritten Public Offering

May 29, 2025

Cemtrex, Inc. Announces Pricing of $1.25 Million Underwritten Public Offering

May 28, 2025

Cemtrex, Inc. Announces Launch of Proposed Public Offering

May 27, 2025

Cemtrex Reports Second Quarter Fiscal Year 2025 Financial Results

May 15, 2025

Cemtrex’s Vicon Secures Prestigious STQC Certification, Strengthening its Position in High-Growth Indian Market

May 12, 2025

Cemtrex Secures $1M Security Technology Order from Major Middle Eastern Media Group

May 7, 2025

Cemtrex’s Vicon Subsidiary Secures $1.2M Order for Border Protection Deployment in Texas

Feb 18, 2025

Cemtrex Reports First Quarter Fiscal Year 2025 Financial Results

Feb 14, 2025

‍

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY CETX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.